The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Multivalent veterinary vaccines. Buy the report here.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

100+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 779,300 patents, there are 100+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, tyrosine kinase inhibitors, immunotherapy radiotherapy combination, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Chimeric flaviviruses, bacteriophage therapy, and microRNA are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are antibody encoding polynucleotide libraries and cell immunomodulation, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Multivalent veterinary vaccines are a key innovation area in pharmaceutical

The term multivalent/polyvalent veterinary vaccine is used to describe either a vaccine candidate with the ability to protect against several diseases or a vaccine candidate that can protect against several strains of a single pathogen used in domestic, livestock or wild animal. These vaccines are composed of active ingredients (antigens) and other adjuvants, inactivators, preservatives and excipients.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of multivalent veterinary vaccines.

Key players in multivalent veterinary vaccines – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to multivalent veterinary vaccines

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
C. H. Boehringer Sohn 1133 Unlock company profile
GSK 473 Unlock company profile
Zoetis 379 Unlock company profile
Mitsubishi Chemical Group 369 Unlock company profile
Merck 320 Unlock company profile
Pfizer 153 Unlock company profile
Sanofi 145 Unlock company profile
Novavax 107 Unlock company profile
Johnson & Johnson 82 Unlock company profile
Intervet 66 Unlock company profile
Sentinext Therapeutics 41 Unlock company profile
Virbac Group 38 Unlock company profile
Takeda Pharmaceutical 35 Unlock company profile
Panacea Biotec 35 Unlock company profile
Eli Lilly 33 Unlock company profile
Novartis 30 Unlock company profile
Air Liquide 26 Unlock company profile
Mymetics 25 Unlock company profile
EpiVax 21 Unlock company profile
United Biomedical 20 Unlock company profile
BFI 19 Unlock company profile
Bharat Biotech 17 Unlock company profile
Catalent 17 Unlock company profile
Centre National de la Recherche Scientifique 17 Unlock company profile
Virginia Tech Intellectual Property 16 Unlock company profile
Redbiotec 15 Unlock company profile
Nutech Ventures 14 Unlock company profile
Academia Sinica 14 Unlock company profile
Laboratorio Avi-Mex SA de CV 12 Unlock company profile
BioGaia 12 Unlock company profile
Wuhan Keqian Biology 12 Unlock company profile
South Dakota Board Of Regents 11 Unlock company profile
Bio Poa 10 Unlock company profile
Calliditas Therapeutics 9 Unlock company profile
Denka 9 Unlock company profile
Bioapplications 9 Unlock company profile
Sinovet (Beijing) Biotechnology 8 Unlock company profile
MBF Therapeutics 8 Unlock company profile
Angany 8 Unlock company profile
Laboratorios Hipra 8 Unlock company profile
Kao 8 Unlock company profile
Cevante Animale 8 Unlock company profile
Temasek 8 Unlock company profile
Verndari 7 Unlock company profile
Meiji 7 Unlock company profile
Assistance Publique - Hopitaux de Paris 7 Unlock company profile
Helvetic Airways 6 Unlock company profile
Medigen Biotechnology 6 Unlock company profile
Vaxxas 6 Unlock company profile
Protatek International 6 Unlock company profile

Source: GlobalData Patent Analytics

C.H. Boehringer Sohn, the parent company of Boehringer Ingelheim group, is the leading patent filer in multivalent veterinary vaccines. The company is one of the largest providers of vaccines, parasiticides and therapeutics, complemented by diagnostics and monitoring platforms. BDA Blen, Marek's Disease Vaccine, Marek's SB1, and Recombitek C3 are some of the veterinary vaccines developed by the company.

In terms of application diversity, Assistance Publique - Hopitaux de Paris is the top company, followed by Angany and Virbac Group. By means of geographic reach, Sentinext Therapeutics holds the top position, while Mitsubishi Chemical Group and GSK are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.